Yan Luk

Yan Luk

Auto-generated profile, based on publicly available information

Yan Luk

Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Thyroid®
Verified
Journal Article
Closed access
MFMan Him Matrix Fung
Man Him Matrix Fung
YLYan Luk
Yan Luk
KYKaren K.W. Yuen
Karen K.W. Yuen
BLBrian Hung Hin Lang
Brian Hung Hin Lang
Objectives Graves' disease(GD) is the most common cause of hyperthyroidism. Antithyroid drug(ATD) is the first-line treatment but when discontinued, >50% of patients suffer relapses. Conventional definitive treatment options include surgery and radioiodine therapy(RAI), each with its own disadvantages. Radiofrequency ablation (RFA) achieved promising short-term remission rates in a previous pilot study. The current study reports our experience of using RFA to treat relapsed GD from the largest cohort of patients with longer period of follow-up. Methods This single-arm prospective study recruited consecutive patients aged ≥18 with persistent / relapsed GD requiring ATD from two tertiary endocrine surgery centers. Those with compressive goiter, suspected thyroid malignancy, moderate to severe Graves' ophthalmopathy, preferred surgery/RAI or pregnant were excluded. Eligible patients received ultrasound-guided RFA to the entire bulk of the thyroid gland. ATDs were discontinued afterwards and thyroid function tests were monitored bi-monthly. The primary outcome was disease remission rate at 24-months follow-up after single-session RFA, defined as being biochemically euthyroid or hypothyroid without ATD. Secondary outcomes were complication rates. Results Of the 100 patients considered, 30 (30.0%) patients were eligible and received RFA. Most were female patients (93.3%). The median total thyroid volume was 23mL (15.9 - 34.5). All completed 24-months follow-up. After single-session RFA, disease remission rates were 60.0% at 12-months and 56.7% at 24-months. Amongst the 13 patients with relapse after RFA, 9 (69%) required lower ATD dose than before RFA; 2 received surgery without complications. Total thyroid volume was the only significant factor associated with relapse after RFA (OR 1.054, 95% CI 1.012 - 1.099, p=0.012). At 24-months, RFA led to disease remission in 100% of the 9 patients with total thyroid volume <20ml, and 35% of patients with total thyroid volume ≥20ml (p=0.007). There was no vocal cord palsy, skin burn, hematoma, or thyroid storm after RFA. Conclusions In a highly selected group of patients with relapsed GD and predominantly small thyroid glands, single-session RFA may achieve disease remission. Smaller total thyroid volume may be a favorable factor associated with disease remission after RFA. The results of this study need to be confirmed with a long-term clinical trial.

15 June 2024 in Surgery
Verified
Journal Article
Closed access
YLYan Luk
Yan Luk
MFMatrix Man Him Fung
Matrix Man Him Fung
DLDavid Tak Wai Lui
David Tak Wai Lui
XLXiaodong Liu
Xiaodong Liu
LLLanlan Li
Lanlan Li
BLBrian Hung Hin Lang
Brian Hung Hin Lang

30 July 2025 in Endocrine Practice
Verified
Journal Article
Closed access
YLYan Luk
Yan Luk
RIRichard Ting Hin Ip
Richard Ting Hin Ip
JLJia-Ning Lee
Jia-Ning Lee
MFMatrix Man Him Fung
Matrix Man Him Fung
DLDavid Tak Wai Lui
David Tak Wai Lui
BLBrian Hung Hin Lang
Brian Hung Hin Lang